Semaglutide trial for children with hypothalamic obesity enters NOT_YET_RECRUITING status — LiveFuture News
Open on LiveFuture.ai →

Semaglutide trial for children with hypothalamic obesity enters NOT_YET_RECRUITING status

ClinicalTrials.gov now lists SEMAFORCRANIO, a phase 3 randomized study of semaglutide versus placebo for hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years.

A new ClinicalTrials.gov registry observation shows SEMAFORCRANIO in NOT_YET_RECRUITING status as of 2026-11-19T00:00:00+00:00. The phase 3 study is testing semaglutide against placebo for hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years, so the immediate takeaway is simple: this is a planned trial, not a finished one.

The sponsor is University Hospital, Angers, and the record says there are no results posted. For families and clinicians, that means the trial is still at the starting line, with only the registry details available so far.

What the study is trying to measure

The study title says SEMAFORCRANIO is multicenter, double-blind, parallel and randomized. In plain language, participants are assigned by chance, and neither the researchers nor the participants know who receives the active drug or the placebo during the blinded part of the study.

Its intervention is listed as Semaglutide (Wegovy) weekly injection in one arm and Placebo weekly Injection in the other. The first co-primary outcome is change in BMI SD score at 40 weeks, and the second is change in BMI SD score at 80 weeks using a delayed-start comparison.

The description also says semaglutide will be escalated over 16 weeks before a maintenance dose of 2.4 mg/week for 24 weeks in the 40-week comparison. That gives the study a very specific treatment plan, even though the clinical outcome is still unknown.

Why this registry entry stands out

Semaglutide is already widely associated with obesity treatment, but this study applies it to a narrower and more specialized group: children with hypothalamic obesity secondary to craniopharyngioma. That makes the registry entry notable because it is not a general obesity trial; it is targeted to a particular medical cause and age range.

The record also sets a long timeline. Primary completion is estimated for 2031-03, which means readers should expect this to remain a developing study for some time. Until results are posted, the registry gives structure and intent, not proof of benefit.

This entry also fits neatly into the wider Obesity & Metabolic special event, where multiple studies are examining obesity from different angles. Those linked studies range from lifestyle and exercise designs to drug studies, but SEMAFORCRANIO is one of the clearest examples of a pediatric, condition-specific drug trial.

Related obesity studies in the same topic stream

Other obesity-related registry observations in the same special event show how broad the research field is right now. One listed study is High-Intensity Interval Training, Inflammatory Biomarkers, and Circulating MicroRNAs in Human Clinical Obesity., another is A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes, and another is A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight (VESPER-SUI).

Together, these studies suggest that the obesity pipeline is not limited to one approach. Some trials focus on medication, some on exercise, and some on behavior or feasibility, while SEMAFORCRANIO focuses on semaglutide in a pediatric obesity subgroup linked to craniopharyngioma.

For readers following this area, the practical question is not whether the trial is complete — it is not — but how this carefully defined study will be positioned once recruitment begins and results eventually appear.